The estimated Net Worth of James B Wyngaarden is at least $34.4 Тысяча dollars as of 12 June 2008. James Wyngaarden owns over 1,284 units of Idera Pharmaceuticals stock worth over $15,775 and over the last 17 years James sold IDRA stock worth over $18,618.
James has made over 5 trades of the Idera Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently James sold 1,284 units of IDRA stock worth $18,618 on 12 June 2008.
The largest trade James's ever made was exercising 20,010 units of Idera Pharmaceuticals stock on 13 March 2008 worth over $80,040. On average, James trades about 2,639 units every 15 days since 2008. As of 12 June 2008 James still owns at least 36,685 units of Idera Pharmaceuticals stock.
You can see the complete history of James Wyngaarden stock trades at the bottom of the page.
James's mailing address filed with the SEC is 3504 STONEYBROOK DRIVE, , DURHAM, NC, 27705.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... и Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: